DRUG TRANSDERMAL DELIVERY SYSTEM

Abstract

A drug transdermal delivery system comprises sponge spicules and a low-frequency sonophoresis device, the drug transdermal delivery system firstly applies a low-frequency sonophoresis to skin using the low-frequency sonophoresis device, a surface of the skin is then massaged with the sponge spicules.

Claims

1. A drug transdermal delivery system, comprising: sponge spicules, and a low-frequency sonophoresis device, wherein: the drug transdermal delivery system firstly applies a low-frequency sonophoresis to skin using the low-frequency sonophoresis device, a surface of the skin is then massaged with the sponge spicules, and a drug is then administered or applied to the surface of the skin; or after the drug transdermal delivery system applies the low-frequency sonophoresis to the skin using the low-frequency sonophoresis device: the surface of the skin is massaged with the sponge spicules, and the drug is administered or applied to the surface of the skin at the same time as the surface of the skin is massaged with the sponge spicules.

2. The drug transdermal delivery system according to claim 1, wherein the sponge spicules are sponge spicules of Haliclona sp.

3. The drug transdermal delivery system according to claim 1, wherein a frequency of the low-frequency sonophoresis is 10-30 kHZ.

4. The drug transdermal delivery system according to claim 1, wherein a frequency of the low-frequency sonophoresis is 15-28 kHZ.

5. A drug transdermal delivery system, wherein: the drug transdermal delivery system comprises a drug that enters into deep layers of skin through a stratum corneum layer of the skin, the deep layers of the skin comprise an active epidermal layer, a dermis layer, and a blood circulation throughout a body comprising the skin, the drug transdermal delivery system comprises sponge spicules and a low-frequency sonophoresis device, the drug transdermal delivery system firstly applies a low-frequency sonophoresis to the skin using the low-frequency sonophoresis device, a surface of the skin is then massaged with the sponge spicules, and the drug is then administered or applied to the surface of the skin; or after the drug transdermal delivery system applies the low-frequency sonophoresis to the skin using the low-frequency sonophoresis device: the surface of the skin is massaged with the sponge spicules, and the drug is administered or applied to the surface of the skin at the same time as the surface of the skin is massaged with the sponge spicules.

6. The drug transdermal delivery system according to claim 5, wherein the sponge spicules are sponge spicules of Haliclona sp.

7. The drug transdermal delivery system according to claim 1, wherein the drug is a hydrophilic drug.

8. A drug transdermal delivery method, comprising: firstly applying a low-frequency sonophoresis to skin, then massaging a surface of the skin with sponge spicules, and then administering a drug to the surface of the skin; or after applying the low-frequency sonophoresis on the skin: then massaging the surface of the skin using sponge spicules, and administering the drug to the surface of the skin at the same time as the surface of the skin is massaged using the sponge spicules.

9. The method according to claim 8, comprising: cleaning the skin before administrating the drug to the surface of the skin.

10. The method according to claim 8, comprising: administering the drug within 72 hours after applying the low-frequency sonophoresis to the skin and then massaging the surface of the skin with the sponge spicules.

11. The drug transdermal delivery system according to claim 1, wherein an output power for the low-frequency sonophoresis is 5-7 W/cm.sup.2.

12. The drug transdermal delivery system according to claim 1, wherein a time during which the low-frequency sonophoresis is applied is 2 minutes or less.

13. The drug transdermal delivery system according to claim 1, wherein a dosage amount of the sponge spicules is 1 mg/cm.sup.2 or less.

14. The method according to claim 8, wherein an output power for the low-frequency sonophoresis is 5-7 W/cm.sup.2.

15. The method according to claim 8, wherein the low-frequency sonophoresis is applied for 2 minutes or less.

16. The method according to claim 8, wherein a dosage amount of the sponge spicules is 1 mg/cm.sup.2 or less.

17. The method according to claim 8, wherein the sponge spicules are sponge spicules of Haliclona sp.

18. The method according to claim 8, wherein a frequency of the low-frequency sonophoresis is 10-30 kHZ.

19. The method according to claim 8, wherein a frequency of the low-frequency sonophoresis is 15-28 kHZ.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] The present disclosure will be further described in combination with the accompanying embodiments and drawings.

[0023] FIG. 1 illustrates a total transdermal absorption of FITC-Dextran-4K (FD-4K) using various transdermal delivery methods.

[0024] FIG. 2 illustrates an accumulated distribution of FD-4K in various skin layers using the various transdermal delivery methods, wherein SC1-10 represents 1.sup.st-10.sup.th layers of stratum corneum along an inward direction (which is separated by a tape peeling method), Epi represents an active epidermal layer, Der represents a dermis layer, and Rec represents a receptor compartment.

[0025] FIGS. 3A-3I illustrate fluorescence distributions of a model drug in the various skin layers.

[0026] FIG. 4 illustrates an analysis diagram of synergistic coefficients using various synergistic administration methods.

[0027] FIGS. 5A-5D illustrate scanning electron microscopes of guinea pig skin.

[0028] FIGS. 6A-6F illustrate staining diagrams of penetration sites of porcine skin.

[0029] FIG. 7 illustrates a diagram of a therapeutic slice of a rabbit ear thrombus model.

[0030] FIGS. 8A and 8B illustrate statistical charts of therapeutic effects for a venous thrombus.

[0031] FIG. 9 illustrates a safety data sheet of a synergistic use of low-frequency sonophoresis and spicules.

DETAILED DESCRIPTION OF THE EMBODIMENTS

[0032] An experimental basis for the embodiments of the present disclosure is as follows:

[0033] 1. Sponge spicules of Haliclona sp.: a preparation method of the sponge spicules of Haliclona sp. may be found in CN201610267764.6, “A method for preparing sponge spicules with a high purity”, which is incorporated herein by reference.

[0034] 2. A sonophoresis device: a JY-92IIN sonophoresis cell disrupter from Ningbo Scientz Biotechnology Co., Ltd.

[0035] Parameters of the sonophoresis cell disrupter are as follows:

[0036] a. An sonophoresis frequency: 20 kHZ;

[0037] b. A total time for sonophoresis: 30 seconds (a working ratio is 50%, a turn-on time for the sonophoresis is 2 seconds, and a turn-off time for the sonophoresis is 2 seconds);

[0038] c. Thermodynamic parameters of an output power for the sonophoresis: 6.8 W/cm.sup.2;

[0039] d. Coupling medium for the sonophoresis: 2 mL of 1% sodium lauryl sulfate (SLS) (which is dissolved in 0.2 mol/L phosphate buffered saline (PBS) buffer solution); and

[0040] e. A distance between an amplitude converter and skin: 10 mm.

[0041] 3. A model drug: fluorescently labeled dextran (a molecular weight of the dextran is 4000, FD-4K, a concentration of the dextran is 1 mg/mL).

[0042] 4. A therapeutic drug: a low-molecular-weight heparin (dalteparin).

Embodiment 1—An Experiment In Vitro

[0043] A circular isolated porcine skin with a diameter of 2 cm and a lipophilic layer removed without damage to layers of the stratum corneum is fixed on a Franz diffusion cell, 12 mL of 0.2 mol/L PBS buffer solution is added into a receptor compartment, and the porcine skin is clamped with a clamp to perform a-e groups using topical administration.

[0044] a. A group using the sonophoresis and then using the spicules: the porcine skin in the Franz diffusion cell is treated with low-frequency sonophoresis for 120 seconds (see the aforementioned section of the parameters of the sonophoresis device), and a solution of a coupling agent in a donor compartment is then sucked out, the porcine skin is washed with 0.2 mol/L PBS buffer solution for three times, 100 μL of a solution of the sponge spicules of Haliclona sp. with a concentration of 20 mg/mL is added into the donor compartment, and the porcine skin is then manually massaged for 2 minutes (a revolution speed is 120 r/min), the residual solution of the sponge spicules of Haliclona sp. is washed away, 150 μL of the model drug is added, and the transdermal delivery in vitro is started.

[0045] b. A group using the spicules and then using the sonophoresis: 100 μL of a solution of the sponge spicules of Haliclona sp. with a concentration of 20 mg/mL is added into the donor compartment of the Franz diffusion cell, and the porcine skin is then manually massaged for 2 minutes (a revolution speed is 120 r/min), the residual solution of the sponge spicules of Haliclona sp. is then washed away, the porcine skin is treated with low-frequency sonophoresis for 120 seconds (which is the same as the group a), a solution of the coupling agent in the donor compartment is then sucked out, the porcine skin is washed with 0.2 mol/L PBS buffer solution for three times, 150 μL of the model drug is then added, and the transdermal delivery in vitro is started.

[0046] c. A massage group using various dosage amounts of the sponge spicules of Haliclona sp.: 100 μL of solutions of the sponge spicules of Haliclona sp. with concentrations of 20 mg/mL, 100 mg/mL, and 10 mg/mL are added into the donor compartment of Franz diffusion cell, the porcine skin is then manually massaged for 2 minutes (a revolution speed is 120 r/min), the residual solutions of the sponge spicules of Haliclona sp. are then washed away, 150 μL of the model drug is respectively added, and the transdermal delivery in vitro is started.

[0047] d. A sonophoresis group: the porcine skin in the Franz diffusion cell is treated with the low-frequency sonophoresis for 120 seconds (which is the same as the steps of the technical solution), and a solution of the coupling agent in the donor compartment is then sucked out, the porcine skin is washed for three times with 0.2 mol/L PBS buffer solution, 150 μL of the model drug is then added, and the transdermal delivery in vitro is started.

[0048] e. A control group: without any treatment, 150 μL of the model drug is added into the donor compartment, and the transdermal delivery in vitro is started.

[0049] A pretreatment using microneedles: a circular isolated porcine skin with a diameter of 2 cm and without damage to layers of the stratum corneum, a lipophilic layer below the dermis layer is removed, a microneedle roller (e.g., German Dermaroller) (a length of microneedles is 0.2 mm, a number of the microneedles is 162) is used to roll on a surface of a skin for one time along a “” shape, and the porcine skin pretreated by the microneedles is fixed on the Franz diffusion cell.

[0050] f. A microneedle group: 150 μL of the model drug is added to porcine skin pretreated by the microneedles, and the transdermal delivery in vitro is started.

[0051] g. A group using the microneedles combined with the sonophoresis: the porcine skin pretreated with the microneedles in the Franz diffusion cell is treated with the low-frequency sonophoresis for 120 seconds (which is the same as the steps of the technical solution), a solution of the coupling agent in the donor compartment is sucked out, and the porcine skin is washed for three times with 0.2 mol/L PBS buffer solution, 150 μL of the model drug is added, and the transdermal delivery in vitro is started.

[0052] Scanning electron microscopy analysis for nude mouse skin: scanning electron micrographs of the nude mouse skin topically pretreated by four groups, including the control group, the sonophoresis group, the group using the spicules and then using the sonophoresis, and the group using the sonophoresis and then using the spicules (the method is the same as the aforementioned method) are taken to analyze morphologies and microstructures of a surface of the skin.

[0053] Staining of topical penetration sites of the skin: the nude mouse skin topically pretreated by three groups, including the sonophoresis group, the 2 mg spicule group, and the group using sonophoresis and then using the spicules (the method is the same as the aforementioned method), a gentian violet solution is added into the donor compartment, stained for 24 hours, and washed by an ethanol solution, and the residue liquid on the surface is absorbed with absorbent paper, a penetration situation of a surface of the stratum corneum layer for the staining solution is observed, the stratum corneum layer and the epidermal layer of the skin are then scrapped by a blade, and a penetration situation of the dermis layer for the staining solution is observed.

[0054] Results:

[0055] 1. After the transdermal delivery in vitro is applied for 16 hours using the various topical drug administration methods of the groups a-g and is isolated using the tape stripping method, drug contents of each skin layer is analyzed, transdermal absorption effects are compared, and the results are shown in FIG. 1. Distribution states of FD-4K in various layers of the skin are compared, and the results are shown in FIGS. 2 and 3A-3I. Synergy index of the transdermal delivery using various synergistic administration methods are analyzed, and the results are shown in FIG. 4.

[0056] 2. After the transdermal delivery in vitro is applied for 16 hours using the various topical drug administration methods, skin tissue is sliced into slices with a thickness of 20 μL using a cryostat microtome. After the slices are fixed and mounted using a resin, a laser confocal microscope (an excitation wavelength is 490 nm, and an emission wavelength is 530 nm) is used to observe distribution states of drug fluorescence in the various layers of the skin, and the results are shown in FIGS. 3A-3I. FIG. 3A illustrates the transdermal delivery using the sonophoresis and then using the 2 mg spicules (cSoSp), FIG. 3B illustrates the transdermal delivery using the 2 mg spicules and then using the sonophoresis (cSpSo), FIG. 3C illustrates the transdermal delivery using the sonophoresis (LFS), FIG. 3D illustrates the transdermal delivery using the 10 mg spicules (SHS5), FIG. 3E illustrates the transdermal delivery using the 2 mg spicules (SHS1), FIG. 3E illustrates the transdermal delivery using the microneedles and then using the sonophoresis (CDRSo), FIG. 3F illustrates the transdermal delivery using the microneedles (DR), and FIG. 3H illustrates the control group (passive).

[0057] 3. According to the results of the scanning electron microscopy analysis of FIGS. 5A-5D, compared with a flat skin surface of the control group (see FIG. 5A), the surface of the nude mouse skin will generate an aperture larger than 2 μm by the sonophoresis (see FIG. 5B). A large number of the spicules pierce into the surface of the guinea pig skin (1 mg/cm.sup.2 of sponge spicules can generate 674±129 microchannels/mm.sup.2, see FIG. 5D) using the sonophoresis and then using the 2 mg spicules, which is far higher than the number of residue spicules of the surface of the skin of the guinea pig using the 2 mg spicules and then using the sonophoresis (approximately 162±91 microchannels/mm.sup.2, see FIG. 5C). FIG. 5A illustrates the control group (Ctr), FIG. 5B illustrates the transdermal delivery using the sonophoresis (LFS), FIG. 5C illustrates the transdermal delivery using the 2 mg spicules and then using the sonophoresis (cSpSo), and FIG. 5D illustrates the transdermal delivery using the sonophoresis and then using the 2 mg spicules (cSoSp).

[0058] 4. According to staining diagrams of penetration sites of the skin of FIGS. 6A-6F, the synergistic effect of the sonophoresis and the spicules enable the surface of the skin to generate a plurality of penetration channels, so that the staining solution can infiltrate the plurality of penetration channels (see FIG. 6A), which is much higher than using the sonophoresis alone or using the spicules alone (See FIGS. 6B and 6C), and scales of the plurality of penetration channels are deeper. Even after the stratum corneum and the epidermal layer are scraped off, a large amount of the staining solution can still infiltrate into the dermis layer (see FIG. 6F), it is difficult for the staining solution to infiltrate into a deep position of the skin using the sonophoresis alone or using the spicules alone, and there is almost no residue staining solution in the dermis layer (see FIGS. 6D and 6E).

[0059] The following results are obtain from an analysis of the quantitative results and the qualitative results.

[0060] 1) The synergistic effect of the low-frequency sonophoresis and the sponge spicules of Haliclona sp. can significantly enhance a transdermal delivery rate (9.5±1.6%) of FD-4K dextran, which is much greater than a transdermal delivery rate using the sponge spicules of Haliclona sp. alone (1.3±0.1%) or using the low frequency sonophoresis alone (1.3±0.5%) and is also significantly higher than a transdermal delivery rate using the microneedle roller (0.5±0.1%) or synergistically using the microneedle roller and the low-frequency sonophoresis (3.4±0.2%).

[0061] 2) After the skin is processed synergistically using the low-frequency sonophoresis and the sponge spicules of Haliclona sp., most drug molecules are accumulated in a deep skin layer below the epidermal layer and completely pass through the stratum corneum barrier. In contrast, the drug has difficulty mostly passing through the stratum corneum barrier using other drug transdermal delivery methods, and the drug is mostly accumulated above the epidermal layer and blocked by the stratum corneum.

[0062] 3) When the skin treated using the sponge spicules is compared with the skin treated using the sonophoresis, the drug is easily delivered to an active epidermal layer when the skin treated using the sponge spicules, which indicates that a function depth of the low-frequency sonophoresis is deeper than that of the sponge spicules with respect to the skin surface.

[0063] 4) When the synergistic coefficients of the various synergistic delivery methods are compared and analyzed, the synergistic effect for using the sonophoresis and then using the spicules (4.1±0.6) is better than the synergistic effect for using the microneedles and then using the sonophoresis (1.9±0.4, p<0.01) and the synergistic effect for using the spicules and then using the sonophoresis (0.4±0.1, p<0.001). Therefore, the synergy for using the sonophoresis and then using the spicules is an optimal synergy with respect to the transdermal delivery cooperative effect.

[0064] 5) A sequence for using the sonophoresis and the spicules effectively influences the effects. The skin should be firstly treated with the low-frequency sonophoresis, the sponge spicules of Haliclona sp. are then used to massage the surface of the skin, and the cooperative effect of the low-frequency sonophoresis and the sponge spicules is achieved. On the contrary, the synergistic effect of firstly using the spicules for massaging the surface of the skin and then using the low-frequency sonophoresis to treat the skin is not obvious, and a drug transdermal delivery rate is not high. Reasons and possible mechanisms are analyzed as follows.

[0065] (1) With respect to synergistically using the spicules and then using the sonophoresis: a pretreatment of the sponge spicules of Haliclona sp. will open the stratum corneum barrier, and a large number of spicules pierce into the surface of the skin, and the low-frequency sonophoresis is then used to provide energy to a coupling medium (e.g., the coupling agent) to induce acoustic cavitation, resulting in bubbles generated in the coupling medium growing rapidly and breaking. However, as the large number of spicules with low weights and small volumes are accumulated on the surface of the skin, break processes of cavitation bubbles generated in the coupling medium on the surface of the skin will also be blocked by the spicules on the surface of the skin, resulting in liquid microjets functioning to increase the sonophoresis penetration rate being blocked. Therefore, hydrophilic channels are significantly reduced. Additionally, the cavitation bubbles on the surface of the skin break, and the sponge spicules of Haliclona sp. piercing into the skin are significantly shed, so that penetration enhancement effect of the sponge spicules of Haliclona sp. is weakened, which is not helpful for the drug molecules continuously penetrating into the skin at a later stage.

[0066] (2) With respect to synergistically using the sonophoresis and then using the spicules: the low-frequency sonophoresis is used to provide energy to a coupling medium to induce acoustic cavitation, resulting in bubbles generated in the coupling medium growing rapidly and breaking. The bubbles are broken on the surface of the skin to generate liquid microjets, so that some hydrophilic channels that are inhomogeneously distributed are generated. Further, sonophoresis energy is transmitted to the surface of the skin to reduce cavitation functions in the lipophilic layer of the skin, a molecular arrangement of the lipophilic layer of the stratum corneum is changed to enable the molecular arrangement to become loose, the sponge spicules then pierce the stratum corneum of the skin using massage, and the skin barrier is then fully opened. Loose effect of the stratum corneum structure induced by the sonophoresis is effectively utilized, the synergistic delivery effect for using the low-frequency sonophoresis and then using the sponge spicules of Haliclona sp. is maximized, and it helps the drug molecules to penetrate into the skin.

[0067] Therefore, when the skin is pretreated using the sonophoresis and then massaged using the sponge spicules of Haliclona sp., a delivery efficiency of the drug molecules is significantly improved.

Embodiment 2—Experiments In Vivo

[0068] A transdermal delivery of low-molecular-weight heparin is used to treat superficial venous thrombus using a synergistic system using the sonophoresis and then using the spicules.

[0069] An experimental method:

[0070] A topical injection of thrombin is used to establish an animal model of a rabbit ear thrombus: hair of an ear of the New Zealand rabbit is carefully shaven off, a blood vessel section from an external ear vein with a length of about 2 cm and having fewer branches is selected, 40 U of the thrombin is injected into the blood vessel section, and a hemostatic clip is used to block a blood flow of the blood vessel section at a proximal end of a heart. After 2 hours, the blood is completely coagulated to form a venous thrombus, and the hemostatic clip is then loosen. A length of the venous thrombus is measured and recorded, and the rabbit ear successfully modeled is sliced into a slice by the cryostat microtome. After the slice is stained by a hematoxylin and eosin (HE) tissue staining method and fixed by the resin, and the slice is mounted for observation.

[0071] With respect to the various administration methods, the rabbits successfully modeled are divided into a therapy group for a proximal venous thrombus and a therapy group for a distal venous thrombus, and the rabbits are topically treated by the low-molecular-weight heparin (300 U/kg rabbit body weight) for therapy. With respect to the therapy group for the proximal venous thrombus, the low-molecular-weight heparin is administered using four topical administration methods after the ear thrombus on a side of the ear modeled is pretreated, respectively namely: a. a smear group; b. a 2 mg spicules group; c. an sonophoresis group; and d. a group using the sonophoresis and then using the spicules. With respect to the therapy group for the distal venous thrombus, the low-molecular-weight heparin is administered using two topical administration methods after a blood vessel on a side of the ear unmodeled is pretreated, respectively namely: a. a group using the sonophoresis and then using the spicules and b. an intravenous injection group. A pretreatment method is the same as described with respect to in vitro.

[0072] Results:

[0073] 1. FIG. 7 illustrates the modeled results of the rabbit ear thrombus. A blood flow of a normal rabbit ear is unobstructed and red, and no thrombus exists in the vessel. After the thrombin is injected to be molded, black strip-shaped thrombus appears in the blood vessel, and the blood vessel is blocked by the thrombus. After the low-molecular-weight heparin is delivered and is treated for 48 hours synergistically using the sonophoresis and then using the spicules, the black strip-shaped thrombus in the blood vessel is almost completely dissolved, and the blood vessel returns to an original state. However, after the low-molecular-weight heparin is delivered and is treated for 48 hours using the spicules alone, the thrombus is not completely dissolved and partially blocks the blood vessel.

[0074] 2. FIGS. 8A and 8B illustrate a measurement, a statistic, and an analysis of thrombus length variations before treatment and after treatment in each group. Referring to FIG. 8A, with respect to the therapy group for the proximal venous thrombus, after delivering the low-molecular-weight heparin synergistically using the sonophoresis and then using the spicules for 48 hours of therapy, the thrombus is basically dissolved, which is better than other groups. Referring to FIG. 8B, with respect to the therapy group for the distal venous thrombus, compared with using intravenous injection, there is no significant difference for thrombus dissolvability degrees after the low-molecular-weight heparin is delivered and is treated for 48 hours at a distal end using the sonophoresis and then using the spicules, which indicates that the low-molecular-weight heparin can be successively delivered into the blood circulation using the delivery method.

[0075] With respect to the therapy results of the rabbit ear thrombus:

[0076] The low-molecular-weight heparin can be successively delivered into subcutaneous tissues to successfully treat the venous thrombus due to the synergistic effect for using the sonophoresis and then using the spicules and enters into the body following the blood circulation. The low-molecular-weight heparin also has a good therapeutic effect with respect to the distal venous thrombus, which indicates an effectiveness of the synergistic system.

[0077] The safety of the technology using the low frequency sonophoresis and then using the sponge spicules of Haliclona sp.:

[0078] 1) An experimental method: 8-10 week old, ordinary female guinea pigs are selected, hair of a surface of a rear flat skin of the ordinary female guinea pig is shaved off without destroying an integrity of the skin of the ordinary female guinea pig, an experimental section with a diameter of 15 mm is circled, a control group and two experimental groups (which are respectively a 10 mg spicules group and a group using the sonophoresis and then using 2 mg spicules, the experimental method is the same as the aforementioned content) are arranged. Referring to FIG. 9, irritation states of the surface of the skin of the ordinary female guinea pig using various administration methods within 72 hours are recorded and observed.

[0079] 2) Experimental results:

[0080] According to Draize skin irritation evaluation standard and Primary Irritation Index (PII) (main irritation index, 0-0.4 represents no irritation, and 0.5-1.9 represents mild irritation) which are internationally accepted, erythema states and edema states of the skin are compared analyzed after each experimental group is complete. The synergistic group using the sonophoresis and then using the 2 mg spicules (PII=0.64) has lower skin irritation than the group using the 10 mg spicules alone (PII=1.61), which indicates that the synergistic system using the low-frequency sonophoresis and then using the sponge spicules of Haliclona sp. has less irritation relative to the skin and effectively increases the safety of use. The synergistic group using the sonophoresis and then using the 2 mg spicules can significantly reduce a dosage amount and a massage intensity of the sponge spicules of Haliclona sp., thereby the skin irritation is greatly reduced.

[0081] The aforementioned embodiments are merely some embodiments of the present disclosure, and the scope of the disclosure of is not limited thereto. Thus, it is intended that the present disclosure cover any modifications and variations of the presently presented embodiments provided they are made without departing from the appended claims and the specification of the present disclosure.